Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment : Derma-Atopic Study in Spain [Artículo traducido] Características de los pacientes, patrones de tratamiento, uso de recursos y costes en adultos con dermatitis atópica moderada-grave en la práctica habitual en España: Estudio Derma-Atopic
Artime, Esther (Lilly)
Serra, Esther (Institut d'Investigació Biomèdica Sant Pau)
Mert, Can (SpaincHaaPacs GmbH)
Díaz-Cerezo, Silvia (Lilly)
Huete, Teresa (Lilly)
Hernández-Subirá, I. (Health Economics and Outcomes Research. Atrys Health)
Lledo-Bryant, Laura (Health Economics and Outcomes Research. Atrys Health)
Sicras-Mainar, Antoni (Health Economics and Outcomes Research. Atrys Health)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Moderate-severe atopic dermatitis (AD) has a significant impact on patients' lives, with many requiring systemic treatment to manage symptoms (e. g. , pruritus). Several drugs are used off-label to treat AD. This study describes sociodemographic/clinical characteristics, treatment patterns, health resource use (HRU) and costs in adults with AD who initiated systemic treatment or phototherapy in routine practice. This retrospective observational study of electronic medical records in the BIG-PAC database identified adults with prior diagnosis of AD (ICD-9: 691. 8 or 692. 9) starting oral corticosteroids, immunosuppressants, biologics or phototherapy between 01/01/2012 and 31/12/2016. Patients were followed for 3 years from treatment initiation, up to 31/12/2019. Data on patient characteristics, treatment patterns, HRU and costs were analyzed descriptively. Patients (N = 1995) had a mean age of 60 years, 64% were female, with a mean time of 23 years since diagnosis (84% were ≥ 18 years at AD onset). Main comorbidities were anxiety (38%), arterial hypertension (36%) and dyslipidemia (35%). Most patients used oral corticosteroids as first systemic (84%; median duration 29 days) and immunosuppressants in 13% of patients (median duration 117 days, 5% cyclosporine and 4% methotrexate). Half of patients required a second line systemic and 12% a third line. The use of immunosuppressants and biologics increased with treatment lines. About 13% of patients received systemic treatments continuously over the 3-year follow-up. The average 3-year per patient cost was 3835 euros, with an average annual cost of 1278 euros. Results suggest a high comorbidity and economic burden in this real-world adult population with AD, and the need for systemic treatments indicated for use in AD.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Castellà
Document:	Article ; recerca ; Versió publicada
Matèria:	Atopic dermatitis ; Costes sanitarios ; Dermatitis atópica ; Estudio observacional ; Healthcare costs ; Observational study ; Resource use ; Systemic treatments ; Tratamientos sistémicos ; Uso de recursos
Publicat a:	Actas dermo-sifiliográficas, Vol. 114 Núm. 1 (enero 2023) , p. T9-T18, ISSN 1578-2190

DOI: 10.1016/j.ad.2022.08.025
PMID: 36030827

10 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats